Werewolf Therapeutics, Inc.
HOWL
$0.63
-$0.03-4.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -92.95% | -90.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -92.95% | -90.55% |
| Cost of Revenue | -24.36% | 22.31% | 27.97% | 3.03% | 3.08% |
| Gross Profit | 20.63% | -36.81% | -82.30% | -70.74% | -101.55% |
| SG&A Expenses | -15.37% | -14.30% | -7.39% | -1.20% | 3.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.61% | 2.89% | 7.97% | 22.55% | 24.87% |
| Operating Income | 17.55% | -8.15% | -25.15% | -63.78% | -81.70% |
| Income Before Tax | 13.75% | -17.26% | -36.13% | -74.15% | -88.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.75% | -17.26% | -36.13% | -74.15% | -88.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.75% | -17.26% | -36.13% | -74.15% | -88.70% |
| EBIT | 17.55% | -8.15% | -25.15% | -63.78% | -81.70% |
| EBITDA | 17.74% | -8.63% | -26.13% | -66.47% | -85.29% |
| EPS Basic | 17.96% | -8.31% | -22.09% | -50.02% | -55.05% |
| Normalized Basic EPS | 17.30% | -9.25% | -23.27% | -48.89% | -53.86% |
| EPS Diluted | 17.81% | -6.42% | -19.52% | -52.68% | -57.83% |
| Normalized Diluted EPS | 17.24% | -9.59% | -23.70% | -48.47% | -53.42% |
| Average Basic Shares Outstanding | 6.19% | 8.88% | 13.12% | 18.17% | 21.57% |
| Average Diluted Shares Outstanding | 6.33% | 8.54% | 12.74% | 18.52% | 21.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |